{
    "Clinical Trial ID": "NCT02447328",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Single Arm",
        "  fulvestrant (Faslodex\u00ae)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Post menopausal status women",
        "  Outpatient or inpatient with locally advanced or metastatic breast cancer who have failed with prior anti-estrogen therapy.",
        "  Estrogen receptor positive",
        "  Radiographic progression of disease after the prior therapy",
        "  Patients who agree to participate in this study and sign the informed consent",
        "Exclusion Criteria:",
        "  Patients who are treated with fulvestrant",
        "  Patients who are being treated with the other antitumor agents",
        "  Pregnancy or lactating women",
        "  History of hypersensitivity to any of included ingredients (eg. Castor oil)",
        "  Patients who are considered not fit for the study by investigators",
        "  Patients who have severe dysfunction of liver or kidney"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)",
        "  Percentage of patients with AEs.",
        "  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient.",
        "Results 1: ",
        "  Arm/Group Title: Single Arm",
        "  Arm/Group Description: fulvestrant (Faslodex  )",
        "  Overall Number of Participants Analyzed: 81",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  Adverse Events(AE): 81.5        (71.3 to 89.3)",
        "  ADR; based on current South Korea label.: 38.3        (27.7 to 49.7)",
        "  Serious AE: 11.1        (5.2 to 20.1)",
        "  Serious ADR: 0        (0 to 4.4)",
        "  Unexpected AE: 71.6        (60.5 to 81.1)",
        "  Unexpected ADR: 24.7        (15.8 to 35.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9/81 (11.11%)",
        "  CHOLANGITIS 1/81 (1.23%)",
        "  contusion of brain 1/81 (1.23%)",
        "  Joint Dislocation 1/81 (1.23%)",
        "  Blood creatinine increased 1/81 (1.23%)",
        "  Bone Pain 1/81 (1.23%)",
        "  Acute lymphocytic leukaemia (in remission) 1/81 (1.23%)",
        "  Hydronephrosis 1/81 (1.23%)",
        "  pelvic pain 1/81 (1.23%)"
    ]
}